Pharma Intelligence
Pharma Intelligence
Send Message
Pharma Intelligence
Stop FollowingPharma Intelligence
View as an RSS Feed
- Eliquis (Apixaban) Approved In Europe - A Blockbuster Opportunity For Bristol-Myers, Pfizer
- Forxiga For Type 2 Diabetes Is A Potential Blockbuster - Buy AstraZeneca
-
Novartis: Breaking Conglomerate Structure Could Unlock 50-60% Shareholder Returns
- Buy Roche Ahead Of ESMO
- Merck - Invest For A 20 To 40 Percent Return Over The Next 2 Years
-
It's Time To Be Optimistic About AstraZeneca
